Get the Stockscreener App
2.21
4.25%
0.09
After Hours:
2.21
Century Therapeutics Inc stock is traded at $2.21, with a volume of 837.08K.
It is up +4.25% in the last 24 hours and down -3.49% over the past month.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
See More
Previous Close:
$2.12
Open:
$2.12
24h Volume:
837.08K
Relative Volume:
0.71
Market Cap:
$398.58M
Revenue:
$109.16M
Net Income/Loss:
$-107.78M
P/E Ratio:
-1.9976
EPS:
-1.1063
Net Cash Flow:
$-95.45M
1W Performance:
+1.84%
1M Performance:
-3.49%
6M Performance:
+273.50%
1Y Performance:
+252.58%
1-Day Range:
$2.085
$2.225
1-Week Range:
$1.98
$2.23
52-Week Range:
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.21 | 382.35M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
445.77 | 112.43B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
616.18 | 64.09B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.00 | 54.88B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.69 | 39.01B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.55 | 31.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | TD Cowen | Buy |
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics (IPSC) executive logs small automatic share sale for taxes - Stock Titan
Century Therapeutics (IPSC) SVP’s automatic 249-share sale covers RSU tax withholding - Stock Titan
Century Therapeutics (NASDAQ: IPSC) CEO has 463 shares withheld for RSU taxes - Stock Titan
Century Therapeutics, Inc. (IPSC) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IPSC) 2026-06-09 - Seeking Alpha
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Century Therapeutics Advances CNTY-813 Diabetes Cell Therapy - TipRanks
Century Therapeutics presents preclinical data on diabetes therapy - Investing.com
Century Therapeutics (NASDAQ: IPSC) details CNTY-813 diabetes cell therapy data - Stock Titan
Experimental islet therapy targets Type 1 diabetes without immunosuppression - Stock Titan
IPSC (NASDAQ: IPSC) Form 144: proposed sale of vested common shares - Stock Titan
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
Number of shareholders of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Century Therapeutics Price Target Announced at $8.00/Share by Mizuho - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Mizuho Initiates Century Therapeutics at Outperform - Moomoo
This GE Aerospace analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Mizuho Initiates Century Therapeutics at Outperform With $8 Price Target - marketscreener.com
Century Therapeutics Initiated at Outperform by Mizuho - Moomoo
Mizuho initiates Century Therapeutics stock coverage at Outperform - Investing.com
Mizuho initiates Century Therapeutics stock coverage at Outperform By Investing.com - Investing.com Canada
Century Advances Diabetes Cell Therapy Toward Human Trials - MyChesCo
IPSC Stock Price, Quote & Chart | CENTURY THERAPEUTICS INC (NASDAQ:IPSC) - ChartMill
Century Therapeutics Q1 2026 Earnings: EPS Surpasses Estimates as Pipeline Progress ContinuesRising Community Picks - Newser
IPSC (NASDAQ: IPSC) resale supplement substitutes Point72 with SILV Fund - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), Century Therapeutics (IPSC) - The Globe and Mail
Century Therapeutics (IPSC) CEO has 31,172 shares withheld to cover RSU tax obligations - Stock Titan
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock - MSN
Century Therapeutics (IPSC) Stock: Slides -1.68%, Support at $2.22 2026-05-15Professional Trade Ideas - newser.com
Point72 group reports 5.96M-share stake in Century Therapeutics (IPSC) - Stock Titan
RTW Investments and R. Wong report 7.1% stake in Century Therapeutics (IPSC) - Stock Titan
Century Therapeutics 1Q Research and Development Expenses $17.1M >IPSC - Moomoo
Versant Venture Management, LLC's Century Therapeutics Inc(IPSC) Holding History - GuruFocus
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Investing News Network
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Century Therapeutics (IPSC) Gains +1.80% — Support Holds at $2.20 2026-05-14Long Setup - newser.com
Century Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Century Therapeutics Reports First Quarter Financial Results and Business Updates - Investing News Network
Century Therapeutics Reports Q1 2026 Financial Results, Advances iPSC-Derived Diabetes and Cancer Therapies, Cash Runway to 2029 - Minichart
Century Therapeutics Q1 Earnings Beat Expectations - Intellectia AI
Century Therapeutics reports Q1 net loss $21.6M, cash runway into Q1 2029 - TradingView
Century Therapeutics 1Q 2026: Revenue ($22.26M), Net income ($21.65M), EPS ($0.11) — 10-Q Summary - TradingView
Century Therapeutics posts smaller-than-expected Q1 net loss on lower R&D spend - TradingView
Century Therapeutics (NASDAQ: IPSC) swings to Q1 2026 loss as prior collaboration revenue rolls off - Stock Titan
Century Therapeutics (IPSC) swings to Q1 2026 loss as one-time collaboration revenue ends - Stock Titan
TradingKey - TradingKey
Douglas Carr, SVP at Century Therapeutics, sells $618 in stock By Investing.com - Investing.com South Africa
Douglas Carr, SVP at Century Therapeutics, sells $618 in stock - Investing.com India
SVP at Century Therapeutics (IPSC) sells shares to cover taxes - Stock Titan
How will Century Therapeutics (IPSC) earnings compare to expectations | Q4 2025: Better Than ExpectedROE - newser.com
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):